Company Overview

Numinus Wellness Inc. is a Canada-based mental health company focused on the development and delivery of psychedelic-assisted therapy and evidence-based mental health services. The company operates at the intersection of healthcare services, clinical research, and emerging therapeutics, primarily addressing conditions such as depression, anxiety, post-traumatic stress disorder (PTSD), and substance use disorders. Its core activities span regulated clinical care, practitioner training, and drug development support within legal frameworks.

The company’s primary revenue drivers are its network of mental health clinics, provision of ketamine-assisted therapy, clinical research services, and professional training programs for psychedelic-assisted therapy. Numinus differentiates itself through an integrated model that combines clinical delivery with research infrastructure and therapist education, positioning the company to participate in both current mental health markets and the potential future commercialization of psychedelic medicines. Founded in 2018 as Rojo Resources Ltd., the company pivoted into mental health and rebranded as Numinus Wellness Inc. in 2020, aligning its strategy with evolving regulatory pathways for psychedelic therapies in Canada and the United States.

Business Operations

Numinus operates through several core business segments, including Numinus Clinics, Numinus Research, and Numinus Training, which collectively support its end-to-end mental health platform. The company generates revenue primarily from patient services delivered through its clinics, research contracts with pharmaceutical and biotechnology companies, and educational programs for licensed healthcare practitioners. Ketamine-assisted therapy currently represents a significant portion of near-term clinical revenue due to its legal status and established reimbursement pathways.

Operations are concentrated in Canada and the United States, with clinics located in major urban centers and research activities conducted under federal and state regulatory approvals. Numinus controls proprietary clinical protocols, data infrastructure, and therapist training curricula designed to scale alongside regulatory expansion. The company has historically expanded through acquisitions of clinic assets and research capabilities, integrating them under a unified operational and clinical governance framework.

Strategic Position & Investments

Numinus’ strategic direction emphasizes scaling its clinic footprint, expanding practitioner training capacity, and participating in clinical trials for psychedelic compounds such as MDMA and psilocybin. Growth initiatives have focused on organic clinic expansion, optimization of utilization rates, and selective acquisitions that enhance geographic reach or specialized clinical expertise. The company has also invested in infrastructure to support late-stage clinical trials and potential future drug commercialization partnerships.

Notable strategic investments include the acquisition of Novamind Inc., which significantly expanded Numinus’ U.S. clinic presence and research capabilities. The company positions itself as a long-term platform for regulated psychedelic care by aligning its operations with public companies, academic institutions, and nonprofit organizations involved in mental health innovation. Its exposure to emerging sectors includes psychedelic drug development support, digital health integration, and outcomes-based mental healthcare models.

Geographic Footprint

Numinus maintains its corporate headquarters in Canada, with operational activities spanning North America. Its clinic network and research operations are distributed across multiple provinces in Canada and several states in the United States, providing access to diverse patient populations and regulatory environments. This bi-national footprint allows the company to participate in both Canada’s federal exemptions framework and the evolving state-level regulatory landscape in the U.S.

The company’s international influence is primarily operational rather than commercial, with its cross-border presence supporting multinational clinical trials and collaborations. While Numinus does not currently operate clinics outside North America, its research and training services have relevance to global mental health markets as regulatory regimes for psychedelic therapies continue to evolve.

Leadership & Governance

Numinus is led by its founder and a management team with backgrounds in healthcare, clinical research, finance, and mental health policy. Leadership emphasizes a clinically rigorous, compliance-driven approach to innovation, with a stated focus on integrating science, safety, and scalability. Governance structures reflect public company standards and healthcare regulatory requirements in both Canada and the United States.

Key executives include:

• Payton Nyquvest – Founder, Chair, and Chief Executive Officer
• Dr. Joe Flanders – President and Chief Medical Officer
• Sharan Sidhu – Chief Financial Officer
• Dr. Devin Kroeker – Chief Strategy Officer